Japan headquatered Takeda's EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The therapy is clinically proven effective in patients with insertion mutations in exon 20 of the growth factor receptor (EGFR) whose disease has progressed during or after platinum-based chemotherapy.
Awny Farajallah, Head of Oncology Affairs Takeda Global Physicians said
